Cowen & Co. Initiates a Buy Rating on Applied Therapeutics Inc (APLT)


Cowen & Co. analyst Marc Frahm initiated coverage with a Buy rating on Applied Therapeutics Inc (APLT) today. The company’s shares closed on Friday at $9.30.

According to TipRanks.com, Frahm is a 3-star analyst with an average return of 4.4% and a 60.0% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and X4 Pharmaceuticals Inc.

Applied Therapeutics Inc has an analyst consensus of Moderate Buy.

See today’s analyst top recommended stocks >>

The company has a one-year high of $10.25 and a one-year low of $7.95. Currently, Applied Therapeutics Inc has an average volume of 135.5K.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APLT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts